ALL NEWS

6390 RESULTS

Stress and Trauma: New Frontier Calling AD Researchers

With the nation at war for eight continuous years, and awareness of the dangers of sports concussions on the rise, a new priority—and opportunity—are taking shape for neurodegenerative disease researchers. In a time of austere budgets, the Department of D

Learn the Skinny on iPS Cells in Neurodegenerative Disease

Are you curious about trying iPS cell lines to model the disease you care about? Intrigued but nebulous on where the field is at? Ready to grow an iPS line but not sure where to turn? Read Madolyn Rogers's four-part series to learn all about who does

Microglia in Health and Disease

Alzforum readers might be forgiven for thinking all microglia do is act prominently, if mysteriously, in Alzheimer's pathogenesis. Not so. A recent flurry of papers shows that microglia can match themselves specifically to GABA synapses. They can rev

Metabolomics Comes of Age

Move over, genome, transcriptome, proteome. The latest ome aims to map every metabolite linked to human health and disease. Metabolomics, although still a nascent field, offers hope for biomarkers and treatments in neurodegenerative disease. The field

Deep-Brain Stimulation: Surgical Relief for Parkinson's and Beyond

In this series, ARF takes stock of deep-brain stimulation after more than a decade of life-altering procedures,  In deep brain stimulation, surgeons implant wires into the brain and hook them up to a pacemaker-like stimulator implanted in the chest, which

DIAN: International Network to Chart AD Preclinical Decade

The rarest kind of Alzheimer's disease, the form that is inherited from parent to child with a cruel 50 percent likelihood, has long been marked by its untapped opportunities. Affected families have made possible both the discovery of the first three

Stress and Alzheimer’s Disease

With the holidays upon us, are your nerves fraying under the combined pressures of work deadlines, shopping, decorating, and entertaining? Now may be a good time to sit back and consider the effects of stress on the brain. Stress per se is not a cause of

Guidelines Bring Needed Change, Though Not Enough for Some

U.S. guidelines for assessing Alzheimer's disease (AD) neuropathology are getting a much-needed facelift. The existing ones, in place since 1997, had fallen out of step with the current understanding of AD as a disease with a long preclinical stage.

Kuopio Hydrocephalus Shunt Biopsy Protocol

In the Finnish city of Kuopio, neurosurgeons collaborate with neurophysiologists and molecular and cellular biologists to make frontal cortex, dura, intraventricular CSF, skin, fat, and other tissue from hydrocephalus patients available for research purpo

ALS Ice Bucket Challenge Returns for a Repeat Performance in 2015

Last year's ice bucket challenge for amyotrophic lateral sclerosis netted $220 million in donations for ALS charities, and the 2015 challenge is off to a strong start with $100,000 from Major League Baseball. Alzforum looks at how all that money is b

Brain Training—Plain Gaming, or a New Vein for Preclinical Research?

If you listen to National Public Radio, watch TV, or surf the Web, chances are you have come across commercials enticing you to “improve your memory” and “unlock your inner genius” with “brain training developed by neuroscientists.”  In search of solid ev

Will Technology Revolutionize Dementia Diagnosis and Care?

As populations age worldwide and the number of people with dementia is set to soar over the next few decades, a crisis in eldercare looms. At the same time, the use of personal technology—smartphones, tablets, wearable monitors—is exploding. Can technolog

Michael J. Fox Foundation Launches Big PD Biomarker Study

A $40 million multicenter biomarker study for Parkinson disease progression is off and running, with enrollment underway at 10 of 18 sites in the U.S. and Europe. In design and operation, the  Parkinson's Progression Markers Initiative  (PPMI) follow

Fallout Continues After Aducanumab Approval

Two weeks after the FDA gave the nod to aducanumab, the aftershocks continue to reverberate. Critics are lambasting the agency, three members of its advisory committee resigned, and the drug’s cost has ignited calls for pricing reform. Meanwhile, Alzheime

Current Filters

  • Date Range : All x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE OF NEWS
DISEASE
TOPIC
BIOMOLECULE